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doi:10.1016/j.ejvs.2009.03.020Abstract Aim: The aim of this prospective study was to assess the clinical effectiveness and
related midterm patency of subintimal angioplasty (SAP) in patients suffering from critical limb
ischaemia (CLI) in a single tertiary care university centre. The secondary aim was to evaluate
the safety and clinical effectiveness of using a re-entry device when re-canalisation by SAP was
unsuccessful.
Methods: From January 2005 to December 2007, consecutive patients suffering from CLI
(Rutherford clinical categories: 4e6) were treated with SAP. All patients included in the study
had occluded SFA (TASC C and D) and underwent clinical and ultrasound follow-up examina-
tions at day 30 and at 3, 6, 9 and 12 months, and then yearly. A re-entry device (Outback, Cor-
dis Corporation, Miami Lakes, Florida, USA in all cases) was only used when re-canalisation by
simple SAP was unsuccessful, and stenting was used when residual stenosis was >30% or there
was a flow-limiting dissection. Factors that could modify the outcome were analysed.
Results: In this study, 145 patients were treated, with a technical success rate of 83.5% (121 of
145) for simple SAP. Stenting was performed in 43% (nZ 62) of successful SAP procedures. No
death occurred in the perioperative period, while the 30-day mortality was 4.8% (7 of 145). The
re-entry device (Outback) was used in 24 cases (16.5%). The technical success of the re-entry
device was 79% (19 of 24), with a 90% success rate of stent placement at the site of re-entry.
Complications occurred in 6.2% of all procedures (nZ 9) (three arterial perforations (2.1%),
three distal embolisations (2.1%), two femoral artery pseudo-aneurysms (1.4%) and one arter-
io-venous fistula (0.7%)). Factors capable of independently affecting the patency were renal
insufficiency (pZ 0.03), current smoking (pZ 0.01) and diabetes (pZ 0.04). The primary
patency at 1 and 3 years was 70% and 34% and the secondary patency at 1 and 3 years was
77% and 43%, respectively. At the same time intervals, the limb-salvage rate was 88% and 49%.ent of Surgery, Unit of Vascular and Endovascular Surgery, University of Siena, Viale Bracci, 53100
ax: þ39 0577 233426.
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Subintimal Angioplasty to Tasc C/D Lesions of the SFA 77Conclusions: SAP with the aid of a re-entry device for TASC C and D lesions of the SFA seems to
be safe and clinically effective in patients suffering from CLI, according to the experience at
our centre. Further follow-up and more data are necessary to confirm these findings.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Definition of poor health status.
Poor cardiac status:
1. Unstable angina,
2. Symptomatic or poorly controlled ectopy/arrhythmia,
3. Poorly compensated or recurrent congestive heart
failure,
4. Ejection fraction less than 25%,
5. Myocardial infarction within 6 months.
Poor pulmonary status:
1. FEV 1 less than 1.2 L or less than 35% of predicted,
2. Supplemental oxygen use medically necessary,
3. Pulmonary hypertension.
FEV: forced expiratory volume, L: litre.Subintimal angioplasty (SAP) is a minimally invasive percu-
taneous technique for the re-canalisation of occluded iliac
and infra-inguinal arteries.1,2 It is usually performed under
local anaesthesia and is based on the creation of a sub-
intimal channel by endoluminal dissection and angioplasty.3
This technique has been used increasingly since it was first
described by Bolia in 1987 and has been proposed as an
alternative to lower limb bypass procedures in critical limb
ischaemia (CLI).4
Re-entry devices have recently been introduced to
facilitate the procedure of re-canalisation.5 In addition,
failed SAP does not preclude the possibility of surgical re-
vascularisation.6
The aim of the present study was to assess the clinical
effectiveness of Subintimal Angioplasty (SAP) and its
midterm patency in SFA-occluded TransAtlantic Inter-
Society Consensus (TASC) C and D lesions (>15 cm) in
patients with CLI who were treated in a single tertiary care
university centre. The secondary aim was to evaluate the
safety and clinical effectiveness of the use of a re-entry
device when re-canalisation by simple SAP was
unsuccessful.
Methods
Patient selection
From January 2005 to December 2007, consecutive patients
suffering from CLI (Rutherford clinical categories: 4e6)7
presenting with long-occluded SFAs/SFAs with long occlu-
sions (TASC C and D e occlusions> 15 cm)8 were treated
with SAP. This treatment was previously reserved for
patients who were not candidates for surgery due to their
poor state of health9 (see Table 1) or for anatomical reasons
(previous ipsilateral bypass, an inadequate greater saphe-
nous vein or a leg ulcer prohibiting distal graft implanta-
tion).10 After limb salvage became common and safe, this
technique was introduced as a first-line treatment in
patients with CLI and SFA occlusions longer than 15 cm. The
number of procedures performed by each operator prior to
inclusion in this study was at least 30 successful SAPs. SAP
has never been used in patients with acute arterial
occlusion.
All patients underwent clinical examination, ABI (anklee
brachial index) measurement and ultrasound examination
before treatment. The angiography was performed at the
same time as the procedure in order to map the femoro-
popliteal lesions accurately and thus optimise the re-
vascularisation strategy. All patients were treated by
a vascular surgeon in an operating theatre equipped with
a portable fluoroscopy unit (GE-OEC 9800; GE Medical
Systems, Salt Lake City, UT, USA). Lesions were defined by
angiography according to the TASC II classification.8 Run-off
vessels were defined as the number of patent crural vesselsafter the procedure in continuation with the femoro-
popliteal segment. Demographic, clinical and intra-operative
variables were entered into a specific database by the
operating team (see Table 2). Data were collected in
a computerised database and was analysed prospectively.
Definitions and end points
Primary technical success was defined as continuous arte-
rial patency to the popliteal artery without any obvious
flow-limiting lesions (absence of a stenosis> 50%). Clinical
outcomes, primary patency, secondary patency and
complications following SAP were reported according to the
‘Recommended standards for reports’ by Rutherford et al.7
The patency rate was based on a colour-flow ultrasound
scan. A change in ABI of at least 0.10 was accepted as
evidence of haemodynamic improvement (and a change of
less than 0.10 was deemed to be a haemodynamic failure).7
In patients in whom the ABI could not be measured accu-
rately (e.g., patients with diabetes and rigid calcified
arteries) it was substituted by the toe pressure (which is
usually unaffected by such conditions) or any measurable
pressure distal to the re-vascularisation. Early mortality
(<30 days) was reported. Limb salvage was defined as no
amputation proximal to the metatarsus.
Endovascular procedure
Anterograde ipsilateral percutaneous femoral access was
preferred when at least 5 cm of a patent proximal segment
of SFA was evident at ultrasonography. A contralateral
approach via a cross-over long sheath was used in the
presence of either SFA occlusion in its origin, high femoral
bifurcation (documented by ultrasound) or obesity. We
were able to check the correct localisation of the CFA
puncture and reduce the risk of retroperitoneal bleeding
using micro-puncture sets and contrast injections under
fluoroscopy.
Table 2 Demographic, clinical and intra-operative
variables.
n %
Limbs 145 100
Mean age SD 71.4 5.5
Range 64e93
Male 93 64
Indications
Critical limb ischaemia 145 100
Rutherford class IV 76 52
Rutherford class V 48 34
Rutherford class VI 21 14
Risk factors
Hypertension 104 72
CAD 78 54
CHF 71 49
COPD 68 47
Diabetes mellitus (100% type II) 74 51
Tobacco use7
None or none for last 10 years 56 39
None current, but smoked
in last 10 years
19 13
Current (þabstinence
< 1 year), <1 pack/day
52 36
Current, >1 pack/day 18 12
Hyperlipidemia 33 23
Previous ipsilateral bypass
(AK fem-pop)
17 (15) 12
Renal insufficiency 48 33
ASA classification
I 0 0
II 16 11
III 106 73
IV 23 16
Intra-operative variables
Stenosis e e
Occlusion 145 100
TASC C (mean length SD) cm 64
(17.12 1.42)
44
TASC D (mean length SD) cm 81
(22.46 1.78)
56
Calcificationa 69 47
Number of run-off vessels
1 89 61
2 44 30
3 12 9
Stented patients 79 54
S.M.A.R.T. Control 33 42
Luminexx 15 19
LifeStent FlexStar 31 39
Ankleebrachial index (mean SD) Range
Pre-operative 0.36 0.08 0.24e0.60
Post-operative 0.57 0.21 0.26e0.93
SD: standard deviation, CAD: coronary artery disease, CHF:
congestive heart disease, COPD: chronic obstructive pulmonary
disease, renal insufficiency serum creatinine> 1.5 mg dL1,
ASA: American Society of Anesthesiology, AK: above the knee.
a Calcification was included when it was >50% of the total
length of the occlusion at intra-operative angiography.
78 C. Setacci et al.A soft, angled, hydrophilic 0.03500 guidewire in combi-
nation with a 5-F, angled, hydrophilic catheter was brought
near the origin of the occlusion. The subintimal plane was
entered by forming a loop at the end of the guidewire and
advancing it, along with the catheter, across the occluded
arterial segment. Indicators of subintimal dissection
included characteristic resistance to wire advancement,
a broad helical path taken by the wire during advancement,
the guidewire loop adapting to the width of the native
vessel and a subtle release of wire resistance with true
lumen re-entry near the distal portion of arterial occlu-
sion.11 Occlusions crossed with the straight tip of a soft
guidewire were considered trans-luminal re-canalisations
and excluded from this study. Following confirmation of
catheter re-entry into the true lumen, balloon angioplasty
was used to dilate the subintimal channel.
A re-entry device was used (Outback, Cordis Corpora-
tion, Miami Lakes, FL, USA in all cases) only when re-
canalisation by simple SAP was unsuccessful.
Stenting was performed only when residual stenosis was
>30% or there was a flow-limiting dissection. The needle of
the Outback catheter was advanced into the subintimal
space under fluoroscopic guidance. Following successful
advancement of a 0.01400 guidewire from the subintimal
space into the true lumen, a 4-F angiographic catheter was
used to replace a 0.03500 guidewire. The rest of the proce-
dure was similar to a normal endovascular treatment/
repair procedure.
All patients were pre-treated with acetylsalicylic acid at
a mean dosage of 125 mg d1 and with clopidogrel or
ticlopidine at a mean dosage of 75 mg d1 or 500 mg d1,
respectively, for at least 4e5 days prior to admission.
Weight-adjusted (70 U kg1) heparin was administered
and repeated as necessary to maintain an activated clotting
time of 225e250 s throughout the procedure. Clopidogrel
(75 mg d1) or ticlopidine (500 mg d1) was continued for at
least 30 days (double anti-platelet therapy) after the
interventional procedure (haemoglobin and white blood
count were checked for 7e10 days after the percutaneous
intervention). Mono anti-platelet therapy (aspirin, clopi-
dogrel or ticlopidine) was continued indefinitely.Follow-up protocol
All patients underwent ipsilateral angiography on comple-
tion of the endovascular procedure.
An ultrasound examination was performed within 48 h of
SAP and repeated at day 30 and 3, 6, 9 and 12 months, and
then yearly. The clinical status of the patients and ABI
index were evaluated at the same intervals, except in
patients with huge ulceration in the leg or calcified
arteries, in whom ABI index was substituted by toe pressure
measurement. The ultrasound examination measured the
patency of the treated artery and any evidence of internal
thrombus. All examinations were performed in the same
vascular laboratory, using the same ultrasound machines
(Ultramark IU-22 and HDI 3500 ATL-Philips, Eindhoven,
Holland). The B-mode imaging frequency was 7 MHz, and
the pulsed-wave Doppler frequency 4 MHz. An insonation
angle of 60 was used, with angle correction where
necessary (40e60). We attempted to maintain the
145 SFA occlusions,
intended for SAP treatment SAP
121 technically
successful
recanalizations
17 patients received SFA
stenting + Outback
(2 SAP+Outback)
24 failed recanalizations
due to failed re-entry
Use of a re-entry device
(Outback – Cordis)
5 failure 
2 BTK vein bypasses
3 hybrid procedures
(remote SFA endarterectomy +
stenting)
19 technically successful
recanalizations
62 patients received SFA
stenting + SAP
(59 SAP alone)
Figure 1 Flow diagram of the patients who underwent subintimal angioplasty (SAP). BTK: below the knee; SFA: superficial
femoral artery.
Subintimal Angioplasty to Tasc C/D Lesions of the SFA 79insonation of 60 all the time in order to standardise the
study methodology. The mean length of follow-up was 595
days (range: 30e1234 days).
Statistical analysis
The data are expressed as mean and standard deviation
(SD) or as median and interquartile range (IQR), depending
on the type of distribution. KaplaneMeier curves were usedTable 3 Clinical outcome.7
1 Month n (%) 6 Mo
þ3 e 3 (2.
þ2 1 (0.7%) 12 (9
þ1 45 (31%) 34 (2
0 41 (28.3%) 37 (2
1 37 (25.5%) 25 (1
2 [minor amputation] 6 [5] (4.2%) 7 [5]
3 [major amputation] 8 [4] (5.5%) 11 [5
Deceased patients 7 (4.8%) 2 (1.
Lost to follow-up 0 3
Patients studied 145 131
In cases in which ABI could not be measured accurately, an index based
excluded from this analysis.
ABI: ankleebrachial index; * Categories referred to the Rutherford cl
D3[Markedly improved: no ischaemic symptoms and any foot lesio
more than 0.90).
D2[Moderately improved: no open foot lesions; still symptomatic b
not normalized but increased by more than 0.10.
D1[Minimally improved: greater than 0.10 increase in ABI but no ca
without an increase in ABI of more than 0.10).
0[ No change: no categorical shift and less than 0.10 change in ABI
L1[Mildly worse: no categorical shift but ABI decreased more than
0.10.
L2[Moderately worse: one category worse or minor amputation.
L3[Markedly worse: more than one category worse or major ampto calculate the primary and secondary patency rates of
angioplastied vessels on an intention-to-treat basis. Factors
that could modify the outcome were analysed (sex, age
(>80 years old), hypertension, diabetes, hyperlipaemia,
renal insufficiency, ASA> II, current smoking, stenting, use
of Outback, pre-operative Rutherford class, TASC C vs.
TASC D). Of all the risk factors examined, those that
showed a significant effect on patency were included in
a Cox multivariate model. A p value< 0.05 was considerednths n (%) 1 Year n (%) 2 Years n (%)
3%) 4 (3.5%) 7 (8%)
.2%) 11 (9.7%) 9 (10.3%)
6%) 27 (24%) 19 (21.8%)
8.2%) 29 (25.7%) 15 (17.4%)
9.1%) 17 (15%) 10 (11.5%)
(5.3%) 8 [3] (7.1%) 6 [3] (6.9%)
] (8.4%) 13[7] (11.5%) 13 [12] (14.9%)
5%) 4 (3.5%) 7 (9.2%)
9 15
113 87
on toe pressure was used. Patients with major amputations were
inical classification.
ns completely healed; ABI essentially ‘‘normalized’’ (increased to
ut only with exercise and improved by at least one category*; ABI
tegorical improvement or vice versa (i.e. upward categorical shift
.
0.10, or downward categorical shift with ABI decrease less than
utations.
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Life Table of reintervention
Interval Start Time
Number 
Entering 
Interval
Number 
Withdrawing 
during Interval
Number 
Exposed to 
Risk
Number of 
Terminal 
Events
Proportion 
Terminating
Proportion 
Surviving
Cumulative 
Proportion 
Surviving at 
End of Interval
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of Interval
0 145 8 141,000 3 .02 .98 .98 .01
90 134 13 127,500 7 .05 .95 .92 .02
180 114 8 110,000 8 .07 .93 .86 .03
270 98 14 91,000 9 .10 .90 .77 .04
360 75 4 73,000 3 .04 .96 .74 .04
450 68 10 63,000 4 .06 .94 .69 .04
540 54 13 47,500 4 .08 .92 .64 .05
630 37 6 34,000 1 .03 .97 .62 .05
720 30 10 25,000 2 .08 .92 .57 .06
810 18 4 16,000 0 .00 1.00 .57 .06
900 14 5 11,500 1 .09 .91 .52 .07
990 8 4 6,000 1 .17 .83 .43 .10
1080 3 1 2,500 0 .00 1.00 .43 .10
1170 2 2 1,000 0 .00 1.00 .43 .10
Figure 2 KaplaneMeier curve and life table analysis for re-intervention. Freedom from re-intervention of 145 SFA occlusions
treated with subintimal angioplasty.
80 C. Setacci et al.statistically significant. SPSS for Windows Version 13.0 (SPSS
Inc., Chicago, IL, USA, www.spss.com) was used for all
statistical analyses.
Results
During the study period 145 patients with SFA occlusions of
more than 15 cm in length (TASC C and D lesions) were
treated using an SAP technique (see flow diagram: Fig. 1).
In the same period 71 other similar SFA lesions were treated
by surgery (nZ 27), hybrid procedures (nZ 48) or by
medical therapy alone (nZ 5). Patient demographics are
presented in Table 2, which shows that the patients
included in this study had many associated co-morbidities
and high ASA classification values. The TASC C lesions were
64 (44%; 17.12 1.42 cm) and the TASC D lesions were 81
(56%; 22.46 1.78 cm).
No intra-operative deaths occurred. The mortality rate
was 4.8% (7 of 145) at 30 days, due to myocardial infarction
(nZ 4) or congestive heart failure (nZ 3).
The technical success rate for SAP was 83.5% (121 of
145). Specifically, the technical success based on the
extent of the SFA occlusion ranged from 86.3% in TASC C
cases to 81% in TASC D cases (pZ 0.34).Regarding the use of a re-entry device, the technical
success rate was 79% (19 of 24). The five cases of unsuc-
cessful re-canalisation with the use of a re-entry device
were due to either calcified arteries or failure to establish
direct flow through the subintimal channel and the true
lumen, due to elastic recoil (see Fig. 1).
‘Spot’ stenting (bare metal stent; mean 4.7 0.8 (range
3e6) cm) was used in 43% (nZ 62) of successful SAP
procedures (see Table 2). Of the procedures using a re-
entry device, 17 out of 19 (90%) patients received at least
one stent at the site of re-entry. Selective stenting was
used in 33 (42%) cases of flow-limiting dissection, 39 (49%)
of residual stenosis> 30% and 7 (9%) with both of the
aforementioned conditions The stents used were: the
S.M.A.R.T. Control stent (nZ 33; Cordis/Johnson & John-
son, Miami Lakes, FL, USA), the Luminexx stent (nZ 15;
C.R. Bard Inc., Murray Hill, NJ, USA) and the LifeStent
FlexStar stent (nZ 31; Edwards Lifesciences, Irvine, CA,
USA) (see Table 2). We used these stents because of their
high radial force. Specifically, the LifeStent FlexStar stent
was used because of its high flexibility, particularly needed
in the transition zone of the SFA to the popliteal artery.
Of the five failures after either a simple SAP or a re-entry
device procedure, two cases were immediately converted
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Life table foroverall primary patency 
Interval Start Time
Number 
Entering 
Interval
Number 
Withdrawing 
during Interval
Number 
Exposed to 
Risk
Number of 
Terminal 
Events
Proportion 
Terminating
Proportion 
Surviving
Cumulative 
Proportion 
Surviving at 
End of Interval
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of Interval
0 145 0 145,000 6 ,04 ,96 ,96 ,02
90 139 0 139,000 8 ,06 ,94 ,90 ,02
180 131 0 131,000 9 ,07 ,93 ,84 ,03
270 122 0 122,000 20 ,16 ,84 ,70 ,04
360 102 5 99,500 3 ,03 ,97 ,68 ,04
450 94 6 91,000 4 ,04 ,96 ,65 ,04
540 84 18 75,000 9 ,12 ,88 ,57 ,04
630 57 6 54,000 3 ,06 ,94 ,54 ,04
720 48 14 41,000 2 ,05 ,95 ,52 ,05
810 32 6 29,000 3 ,10 ,90 ,46 ,05
900 23 7 19,500 0 ,00 1,00 ,46 ,05
990 16 6 13,000 2 ,15 ,85 ,39 ,06
1080 8 0 8,000 0 ,00 1,00 ,39 ,06
1170 8 5 5,500 1 ,18 ,82 ,32 ,08
Figure 3 KaplaneMeier curves and life table analysis for primary (A) and secondary (B) patency. Overall primary and secondary
patency of subintimal angioplasty procedures combined with the use of Outback and selective stenting. Vertical lines indicate 1
month, 3, 6, 12, 24 and 36-month follow-ups.
Subintimal Angioplasty to Tasc C/D Lesions of the SFA 81to open surgery and the other three to a hybrid re-
vascularisation.
Complications occurred in 6.2% of all procedures (nZ 9)
and included three arterial perforations (2.1%), two
femoral artery pseudo-aneurysms (1.4%) (one of which
resulted in a retroperitoneal haematoma), three episodes
of distal embolisation (2.1%) and one arterio-venous fistula
(0.7%).
Only the retroperitoneal haematoma required an urgent
open surgical intervention for correction. The cases of
arterial perforation required a long balloon inflation (one
case) or a surgical bypass (two cases e below-the-knee vein
bypass).
Distal embolisation was remedied using aspiration
catheters or the ‘push and park’ technique.12 No surgical
embolectomy was required following SAP.
The clinical outcomes at 1, 6, 12 and 24 months are
shown in Table 3. The ABI index was not properly evaluable
in only 12 (8%) patients during the entire follow-up period.
Table 3 shows that the clinical benefits of SAP were slightly
better in the first 6 months of follow-up following the
procedure and subsequently the percentage of patients
who were improving or stable remained constant.The KaplaneMeier curve and life table analysis of re-
intervention during the entire follow-up period are shown
in Table 2. The re-interventions performed were either
percutaneous transluminal angioplasty (PTA) in failing SAP
(PTAþ stenting in selected cases) or bypass surgery in
failed SAP (the vein was used whenever possible). The
Kaplan-Meier curve and life table analysis for re-interven-
tion are shown in Fig. 2. The KaplaneMeier curves and life
table analysis of the overall primary and secondary patency
are reported in Figs. 3. The primary patency and secondary
patency were 70% and 77% at 1 year follow-up; 53% and 61%
at 2 years and 34% and 43% at 3 years. Figs. 4 and 5 show
(respectively) KaplaneMeier curves and life table analysis
of patency for selective SAPþ stenting vs. SAPþ no selec-
tive stenting procedures, and for SAPþ re-entry device vs.
SAPþ no re-entry device. The use of an Outback device and
selective stenting did not affect the patency in a statisti-
cally significant way (see Table 4).
The limb salvage was 88%, 76% and 49% at 1, 2 and 3
years respectively (see KaplaneMeier curve and life table
analysis in Fig. 6).
All amputation cases had infected gangrene of the
forefoot or, in the majority of cases, the entire foot and the
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Life table for overall secondary patency
Interval Start Time
Number 
Entering 
Interval
Number 
Withdrawing 
during Interval
Number 
Exposed to 
Risk
Number of 
Terminal 
Events
Proportion 
Terminating
Proportion 
Surviving
Cumulative 
Proportion 
Surviving at 
End of Interval
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of Interval
0 145 0 145,000 6 ,04 ,96 ,96 ,02
90 139 1 138,500 7 ,05 ,95 ,91 ,02
180 131 3 129,500 6 ,05 ,95 ,87 ,03
270 122 6 119,000 14 ,12 ,88 ,77 ,04
360 102 6 99,000 2 ,02 ,98 ,75 ,04
450 94 6 91,000 4 ,04 ,96 ,72 ,04
540 84 21 73,500 6 ,08 ,92 ,66 ,04
630 57 6 54,000 3 ,06 ,94 ,62 ,04
720 48 14 41,000 2 ,05 ,95 ,59 ,05
810 32 7 28,500 2 ,07 ,93 ,55 ,05
900 23 7 19,500 0 ,00 1,00 ,55 ,05
990 16 7 12,500 1 ,08 ,92 ,51 ,06
1080 8 0 8,000 0 ,00 1,00 ,51 ,06
1170 8 5 5,500 1 ,18 ,82 ,41 ,10
Figure 3 Continued.
82 C. Setacci et al.distal part of the leg, leading to an above-the-knee
amputation.
The factors that independently affected patency were
renal insufficiency (pZ 0.03), current smoking (pZ 0.01)
and diabetes (pZ 0.04) (see Table 4).Discussion
SAP is a minimally invasive technique that is well tolerated
by most patients and requires a modest amount of equip-
ment.13 The advantages of a percutaneous interventional
procedure over bypass surgery are avoidance of the
complications of general anaesthesia, making an incision in
an ischaemic leg and healing complications as well as less
systemic stress (local anaesthesia) and faster recovery and
ambulation.
Moreover, a re-do procedure might be more readily
repeated than surgery, with the possibility of offering
future surgical intervention if needed. The procedure
needs to be performed by an experienced team composed
of trained operators. Our team is composed of vascular
surgeons, who were included in this study on the condition
that they had completed a learning curve of at least 30successful SAP procedures. In our centre we try to use
a standardised approach: a brief (SAP) procedure of
30e40 min and use of a re-entry device is advised when
accessing the true lumen is difficult, so as not to dissect
the popliteal artery or threaten the supragenicular collat-
erals. If the procedure cannot be concluded safely, we
continue the intervention surgically or use a hybrid
approach. The presence of a vascular surgeon in the team
is important as, in the case of a failed SAP, the first
intervention should not preclude the possibility of further
surgical re-vascularisation.6
In a recent systematic article regarding SAP, Met et al.14
showed that this technique can play an important role in
the treatment of peripheral arterial disease and can be
considered as a ‘temporary bypass’ to provide wound
healing and limb salvage, especially in the case of critical
limb ischaemia. In our experience the association of SAP
with a re-entry device has guaranteed good midterm results
in patients suffering from CLI. This study has reported TASC
C and D treatment. Although the TASC documents recom-
mend that TASC D lesions be treated with open surgical
reconstruction,15 the technical success of SAP in our
patients did not differ significantly between the two TASC
groups in our study.
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SAP
Life Table of SAP vs. SAP + selective stenting
First-order Controls Interval Start Time
Number 
Entering 
Interval
Number 
Withdrawing 
during Interval
Number 
Exposed to 
Risk
Number of 
Terminal 
Events
Proportion 
Terminating
Proportion 
Surviving
Cumulative 
Proportion 
Surviving at 
End of Interval
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of Interval
stent 0: no stenting 0 60 0 60,000 2 ,03 ,97 ,97 ,02
90 58 0 58,000 2 ,03 ,97 ,93 ,03
180 56 0 56,000 2 ,04 ,96 ,90 ,04
270 54 0 54,000 7 ,13 ,87 ,78 ,05
360 47 2 46,000 1 ,02 ,98 ,77 ,05
450 44 3 42,500 2 ,05 ,95 ,73 ,06
540 39 12 33,000 4 ,12 ,88 ,64 ,07
630 23 2 22,000 2 ,09 ,91 ,58 ,07
720 19 5 16,500 0 ,00 1,00 ,58 ,07
810 14 4 12,000 1 ,08 ,92 ,53 ,08
900 9 4 7,000 0 ,00 1,00 ,53 ,08
990 5 1 4,500 1 ,22 ,78 ,42 ,12
1080 3 0 3,000 0 ,00 1,00 ,42 ,12
1: stenting 0 85 0 85,000 4 ,05 ,95 ,95 ,02
90 81 0 81,000 6 ,07 ,93 ,88 ,03
180 75 0 75,000 7 ,09 ,91 ,80 ,04
270 68 0 68,000 13 ,19 ,81 ,65 ,05
360 55 3 53,500 2 ,04 ,96 ,62 ,05
450 50 3 48,500 2 ,04 ,96 ,60 ,05
540 45 6 42,000 5 ,12 ,88 ,53 ,06
630 34 4 32,000 1 ,03 ,97 ,51 ,06
720 29 9 24,500 2 ,08 ,92 ,47 ,06
810 18 2 17,000 2 ,12 ,88 ,41 ,06
900 14 3 12,500 0 ,00 1,00 ,41 ,06
990 11 5 8,500 1 ,12 ,88 ,36 ,07
1080 5 0 5,000 0 ,00 1,00 ,36 ,07
Figure 4 KaplaneMeier curve and life table analysis for primary patency (SAP vs. SAPþ selective stenting). Primary patency of
145 SFA occlusions treated with subintimal angioplasty (SAP) or SAPþ selective stenting.
Subintimal Angioplasty to Tasc C/D Lesions of the SFA 83Furthermore, our patients could be classified as a group
at high risk for surgery. In fact, coronary artery disease
(CAD) and Congestive heart disease (CHF) accounted for
54% and 49% of all patients respectively, while an ASA
classification of equal to or more than III was present in 89%
of the overall study population.
For these seriously ill patients, a mini-invasive treat-
ment was chosen as the first-line treatment in order to
avoid major surgical stress.
According to reports in many articles, SAP has lower
patency rates than surgery,1e4,14 and for the time being,
bypass treatment remains ‘the gold standard’ for critical
limb ischaemia,16,17 although there are no comparative
studies between SAPand surgery. In randomised trials such asBASIL,18 few patients seemed to be eligible for random-
isation due to their local anatomy, and many tended to
prefer a minimally invasive treatment. Moreover, infra-
inguinal bypass surgery is demanding on resources and costly.
In our centre, the mean cost of a surgical procedure is
about 28% higher than that of an interventional procedure
(SAP plus selective stenting): surgery has amean cost of 6800
Euros compared to a mean cost of 4900 Euros for an endo-
vascular approach. The adjunctive cost of a re-entry device
balances the costs of the two different procedures (SAPþ a
re-entry device vs. bypass surgery). Moreover, an adjunctive
stent increases the cost by another 400e600 Euros.
Our one- and two-year primary and secondary patency
results were similar to those reported in other endovascular
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First-order Controls Interval Start Time 
Number 
Entering 
Interval 
Number 
Withdrawing 
during Interval 
Number 
Exposed to 
Risk 
Number of 
Terminal 
Events 
Proportion 
Terminating 
Proportion 
Surviving 
Cumulative 
Proportion 
Surviving at 
End of Interval 
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of Interval 
outback 0: no outback use 0 121 0 121,000 4 ,03 ,97 ,97 ,02 
    90 117 0 117,000 5 ,04 ,96 ,93 ,02 
    180 112 0 112,000 7 ,06 ,94 ,87 ,03 
    270 105 0 105,000 19 ,18 ,82 ,71 ,04 
    360 86 5 83,500 3 ,04 ,96 ,69 ,04 
    450 78 5 75,500 4 ,05 ,95 ,65 ,04 
    540 69 15 61,500 7 ,11 ,89 ,58 ,05 
    630 47 6 44,000 3 ,07 ,93 ,54 ,05 
    720 38 10 33,000 2 ,06 ,94 ,50 ,05 
    810 26 6 23,000 2 ,09 ,91 ,46 ,06 
    900 18 6 15,000 0 ,00 1,00 ,46 ,06 
    990 12 3 10,500 1 ,10 ,90 ,42 ,06 
    1080 8 0 8,000 0 ,00 1,00 ,42 ,06 
  1: outback use 0 24 0 24,000 2 ,08 ,92 ,92 ,06 
    90 22 0 22,000 3 ,14 ,86 ,79 ,08 
    180 19 0 19,000 2 ,11 ,89 ,71 ,09 
    270 17 0 17,000 1 ,06 ,94 ,67 ,10 
    360 16 0 16,000 0 ,00 1,00 ,67 ,10 
    450 16 1 15,500 0 ,00 1,00 ,67 ,10 
    540 15 3 13,500 2 ,15 ,85 ,57 ,10 
    630 10 0 10,000 0 ,00 1,00 ,57 ,10 
    720 10 4 8,000 0 ,00 1,00 ,57 ,10 
    810 6 0 6,000 1 ,17 ,83 ,47 ,12 
    900 5 1 4,500 0 ,00 1,00 ,47 ,12 
    990 4 3 2,500 1 ,40 ,60 ,28 ,16 
 
 
Figure 5 KaplaneMeier curve and life table analysis for primary patency (SAP vs. SAPþOutback use). Primary patency of 145 SFA
occlusions treated with subintimal angioplasty (SAP) or SAPþOutback.
84 C. Setacci et al.studies, which presented overall patency rates for SAP at 12
months ranging from 53% to 90%.14,19e23 In a recent review
of 506 infra-inguinal arterial occlusions, Scott et al.11
reported primary patency of 45% and 25% at 12 and 36
months respectively, while secondary patency was 76% and
50% at the same time intervals.
In our experience we did not observe much difference
between primary and secondary patency. A possible expla-
nationcould lie in thedifference in the signs shownbypatients
(both claudication and CLI) and the different levels of lesions
in the leg (femoral, popliteal and tibial districts).
Primary technical failure is the inability to re-enter the
true lumen in a patent distal vessel. Different techniques
and new devices have been reported to facilitate re-entryinto the true lumen.24e26 The Outback device (Cordis
Corporation, Miami Lakes, FL, USA) was used in this study.
The Outback re-entry device was voluntarily removed from
the market between August 2008 and January 2009 (and has
since been re-introduced) because of a higher-than-
expected incidence of the piercing needle failing to retract
safely, as described in an FDA report.27 However, in our
experience the technical success of the device was satis-
factory. The five failures we faced were due either to
calcified arteries or failure of the angioplasty catheter to
establish forward flow through the subintimal channel. We
observed only 1 case of arterial perforation that required
a staged surgical bypass. No technical problems due to the
device itself were registered in our database.
Table 4 Cox multivariate analysis of subintimal angio-
plasty patency by risk factors examined.
Risk factors B SE Wald df p Value Exp(B)
Male gender 0.31 0.26 1.41 1 0.23 1.36
Age (>80 years
old)
0.04 0.02 3.68 1 0.06 1.04
Hypertension 0.19 0.27 0.47 1 0.49 0.83
Diabetes 0.60 0.30 4.14 1 0.04 0.55
Hyperlipaemia 0.27 0.30 0.81 1 0.37 0.76
Renal insufficiency 0.64 0.29 4.71 1 0.03 1.89
ASA> II 0.39 0.28 1.87 1 0.17 1.47
Current smoking 0.31 0.12 6.62 1 0.01 1.37
Stenting 0.02 0.25 0.01 1 0.94 1.02
Use of Outback 0.67 0.39 3.01 1 0.08 0.51
Rutherford class 4 0.31 0.35 0.77 1 0.38 0.74
Rutherford class 5 0.02 0.38 0.00 1 0.95 0.98
TASC C 0.27 1.07 0.06 1 0.80 1.31
TASC D 0.21 1.09 0.04 1 0.85 0.81
Subintimal Angioplasty to Tasc C/D Lesions of the SFA 85With regard to the possible factors that might affect the
patency rate of SAP, we found that diabetes, renal insuf-
ficiency and current smoking were the most important.
Reekers and Bolia.28 and Aleksynas and Kaupas29 found that90
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Life table of limb salvage
Interval Start Time
Number 
Entering 
Interval
Number 
Withdrawing 
during Interval
Number 
Exposed to 
Risk
Number 
Termina
Events
0 145 5 142,500
90 135 6 132,000
180 128 6 125,000
270 120 18 111,000
360 96 6 93,000
450 89 8 85,000
540 79 23 67,500
630 55 8 51,000
720 44 12 38,000
810 30 5 27,500
900 22 6 19,000
990 14 6 11,000
1080 6 0 6,000
Figure 6 KaplaneMeier curve and life table analysis for limb salv
angioplasty.arterial calcification was predictive of technical failure.
Antusevas et al.22 reported that calcification of the SFA
influenced technical success but did not affect primary-
assisted patency, while distal run-off vessels, occlusion
length and smoking were not significantly associated with
primary or primary-assisted patency.
London et al.1 found that run-off vessels, smoking and
occlusion length were independent risk factors for re-
occlusion. Lazaris et al.20 recently described a clinical
study of 51 infra-inguinal SAP procedures in 46 patients
suffering from CLI. The 12-month patency in patients
with more than one run-off vessel was 81%, compared to
25% in patients with only one run-off vessel. Regarding
the length of occluded SFA, the risk of re-occlusion was
1.02 for every centimetre of occlusion (pZ 0.049).20
Comparable results for percutaneous trans-luminal infra-
inguinal angioplasty have also been reported by other
investigators.30e32
Our patients were treated with double anti-platelet
therapy for a month postoperatively and subsequently with
mono anti-platelet therapy, continued indefinitely. Yilmaz
et al.23 reported that the use of the anticoagulant warfarin
may significantly improve the patency of an SAP procedure,
although overall patency rates are still lower than those
reported for bypass surgery.12
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l Proportion 
Terminating
Proportion 
Surviving
Cumulative 
Proportion 
Surviving at 
End of Interval
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of Interval
5 ,04 ,96 ,96 ,02
1 ,01 ,99 ,96 ,02
2 ,02 ,98 ,94 ,02
6 ,05 ,95 ,89 ,03
1 ,01 ,99 ,88 ,03
2 ,02 ,98 ,86 ,03
1 ,01 ,99 ,85 ,03
3 ,06 ,94 ,80 ,04
2 ,05 ,95 ,76 ,05
3 ,11 ,89 ,67 ,06
2 ,11 ,89 ,60 ,07
2 ,18 ,82 ,49 ,09
0 ,00 1,00 ,49 ,09
age. Limb salvage of 145 SFA occlusions treated with subintimal
86 C. Setacci et al.In our experience, we found it useful to carefully apply
spot-stenting in the case of either residual stenosis> 30% or
a flow-limiting dissection. We tried to avoid covering long
lesions with multiple stents. It could be argued that a more
extensive use of stents can improve technical success on
a long-term basis, although Treiman et al.33 demonstrated
that routinely placing stents across the entire re-canalised
segment could contribute to a high rate of late failure. In
contrast, selective stent use after SAP can provide excel-
lent late limb salvage, as reported by Schmieder et al.34
Our limb-salvage rate was similar to those reported in
the TASC II document8 and the cases of failing/failed SAPs
identified during the follow-up period were probably due to
the combination of endovascular re-do and surgical bypass.
Another key point for successful midterm results after an
endovascular procedure is an appropriate follow-up
protocol. We agree with the strategy of Florenes et al.19
who attributed their excellent results to the fact that all
the patients were placed in a duplex surveillance pro-
gramme and any significant stenosis was treated with PTA
or, in selected cases, with PTAþ stenting. If an occlusion
occurred and the patient had persistent CLI, bypass surgery
was performed (vein grafting was used whenever possible).
Although this study is prospective, it does not scrutinise
all the variables that may have influenced the outcome of
the SAP procedure (e.g., calcification and run-off vessel
number, as analysed by other authors). The analysis lacks
the statistical power to effectively differentiate the rela-
tive importance of several other variables that occurred at
a low frequency in the SAP plus re-entry device group.
Moreover, this study was not controlled and randomised and
the centre’s first approach to endovascular therapy for such
SFA lesions is probably an important bias as well.Conclusions
In the experience at our centre, subintimal angioplasty with
the aid of a re-entry device for TASC C and D lesions of the
SFA seems to be safe and clinically effective in patients
suffering from CLI. Patency was affected independently by
diabetes, renal insufficiency and current smoking in our
study. Further follow-up and more data are necessary to
confirm these findings.Conflict of Interest
There is no financial arrangement or other relationship that
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